Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


WellGen update

This article was originally published in The Tan Sheet

Executive Summary

Capital raised from WellGen's most recent round of funding will reinforce its leadership position in the emerging field of nutrigenomics and functional foods, the New Brunswick, N.J.-based firm announces Oct. 29. Specifically, the funding will enable the firm to "advance its anti-obesity ingredient for functional foods, including the launch of a human study that has already received Institutional Review Board approval, and to conduct further studies of its recently patented product WG0401," company notes. WellGen received a patent for its WG0401 ingredient covering its use for arthritis, inflammation and cancer in July; the product was developed through nutrigenomics, the study of how nutrients affect gene expression (1"The Tan Sheet" July 16, 2007, In Brief)...

You may also be interested in...

Nutrigenomics ingredient

WellGen's black tea extract product, WG0401, received a patent covering uses of the product for arthritis, inflammation and cancer, the biotech firm states July 10. The firm says it developed the ingredient through nutrigenomics - the study of how nutrients affect gene expression. "We believe WG0401 is the first nutrigenomics-developed ingredient to be commercialized for consumer application," states WellGen CEO, Kathleen P. Mullinix. The product will be marketed to the supplement industry as a functional food ingredient aimed at promoting joint health and comfort, anti-aging and immune-defense support as well as contributing to cardiovascular health, the company says. WellGen is in the process of finalizing a distribution agreement with Charles Bowman and Company to facilitate its entry into the marketplace, the firm says. The North Brunswick, N.J.-based firm announced earlier in the year it anticipates WG0401 will hit the market mid-year (1"The Tan Sheet" May 28, 2007, p. 14)...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts